A Randomised, Double-blind, Phase I/II Study to Evaluate the PK, PD, Safety, and Efficacy Between HLX01 and Rituximab in Patients With Moderate to Severe Rheumatoid Arthritis and Inadequate Response to Treatment With DMARDs
Sponsor: Shanghai Henlius Biotech
This PHASE1/PHASE2 trial investigates Rheumatoid Arthritis and is currently completed. Shanghai Henlius Biotech leads this study, which shows 7 recorded versions since 2016 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.
Status Flow
Change History
7 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE1/PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE1/PHASE2
Phase: PHASE1_PHASE2 → PHASE1/PHASE2
-
Jun 2022 — Jul 2024 [monthly]
Completed PHASE1_PHASE2
-
Jan 2021 — Jun 2022 [monthly]
Completed PHASE1_PHASE2
-
Nov 2018 — Jan 2021 [monthly]
Completed PHASE1_PHASE2
Status: Active Not Recruiting → Completed
▶ Show 2 earlier versions
-
Jun 2018 — Nov 2018 [monthly]
Active Not Recruiting PHASE1_PHASE2
-
Dec 2017 — Jun 2018 [monthly]
Active Not Recruiting PHASE1_PHASE2
First recorded
Feb 2016
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Shanghai Henlius Biotech
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
No location information available.